Considered a niche peptide with strong interest in sleep and neurological signaling investigations

CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
Cox, JE
For those on antidiabetic medications, such as insulin or oral hypoglycemic agents, glutathione may alter the efficacy of these drugs, potentially leading to hypo- or hyperglycemia
Injection procedure Clean technique prevents infections
The tubes containing the samples were placed into liquid nitrogen for 20 min, and then transferred into a 37C water bath for 10 min, which was repeated two times